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Peptides presented at the cell surface reflect the protein content of the cell; those on HLA class I molecules comprise the
critical peptidome elements interacting with CD8 T lymphocytes. We hypothesize that peptidomes from ex vivo tumour samples
encompass immunogenic tumour antigens. Here, we uncover 46000 HLA-bound peptides from HLA-A*02 + glioblastoma, of
which over 3000 were restricted by HLA-A*02. We prioritized in-depth investigation of 10 glioblastoma-associated antigens
based on high expression in tumours, very low or absent expression in healthy tissues, implication in gliomagenesis and
immunogenicity. Patients with glioblastoma showed no T cell tolerance to these peptides. Moreover, we demonstrated specific
lysis of tumour cells by patients’ CD8 + T cells in vitro. In vivo, glioblastoma-specific CD8 + T cells were present at the tumour
site. Overall, our data show the physiological relevance of the peptidome approach and provide a critical advance for designing
a rational glioblastoma immunotherapy. The peptides identified in our study are currently being tested as a multipeptide vaccine
(IMA950) in patients with glioblastoma.
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Introduction
T lymphocytes monitor peptides presented by major histocompati-
bility complex molecules [human leukocyte antigen (HLA) in
humans] at the cell surface; those bound by HLA class I molecules,
the HLA class I peptidome, are recognized by CD8 T lymphocytes.
The identity of such HLA-associated peptidomes remains largely
unknown, although their precise knowledge could lead to valuable
information about the biology of cells, and particularly tumour
cells. This would enhance understanding of tumorigenesis and
tumour–immune system interactions. In the last 10 years, studies
using proteomics have looked to tumours to identify biomarkers of
disease or tumour-associated proteins for targeted therapies
including immunotherapy, but few studies (Weinschenk et al.,
2002) have thus far analysed tumours ex vivo at the peptide
level. Indeed, isolating and identifying such peptides requires
sophisticated techniques that are today available with the devel-
opment of highly sensitive liquid chromatography followed by
mass spectrometry analysis (LC–MS) (Weinschenk et al., 2002;
Lemmel and Stevanovic, 2003).
In the identification of tumour-associated targets for immuno-
therapy, the advantage of peptidomics over proteomics is the
guarantee of selecting peptides that are naturally present at the
cell surface. To date, the vast majority of antigens routinely used
for peptide vaccination have been identified using prediction algo-
rithms, reverse immunology techniques, in vitro cultured tumour
cell lines or complementary DNA libraries (Sampson et al., 2010;
Okada et al., 2011). However, these in vitro or in silico tech-
niques do not investigate direct peptide presentation in vivo and
do not ensure that the selected peptides are naturally present at
the tumour cell surface at levels sufficient to allow cytotoxic
T lymphocyte recognition.
Glioblastoma multiforme (GBM, grade IV astrocytoma) is a
deadly tumour of the brain for which current treatments only
marginally improve patients’ prognosis. Thus, it is imperative to
develop new treatment modalities, among which immunotherapy
is very promising. Therefore, to assess the potential of using
HLA-associated tumour peptidomes as a source of tumour-
associated antigens to be used in immunotherapy, we submitted
HLA/peptide complexes isolated from HLA-A*02 + GBM samples
to peptide elution and identification using LC–MS (Weinschenk
et al., 2002; Singh-Jasuja et al., 2004). We then selected
tumour-associated peptides with high GBM-associated expression
and strong immunogenicity and characterized them.
Materials and methods
Additional information is available in the online Supplementary material.
Patients and samples
HLA-A*02-positive patients with GBM (stage IV glioma) were included
in this study, which conformed to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the Institutional Review
Board of all centres concerned. All patients gave written informed
consent. Material for peptide elution was collected at the time of
surgery before any treatment. Brain tumour samples were processed
immediately and frozen in liquid nitrogen for peptide elution. Normal
brain samples and non-CNS tissues were processed similarly. Peripheral
blood was collected in heparin tubes and peripheral blood mononu-
clear cells were isolated using a Ficoll gradient (PAA). The T2, U118
and K562 cell lines (ATCC) were maintained in RPMI medium
containing 10% foetal calf serum (Invitrogen). T2 cells were verified
for HLA-A2 expression by antibody staining. The K562 cell line
was verified for natural killer-dependent killing using natural killer
cells cultured with IL-2 and IL-15 in a 4 h cytotoxicity assay. The
GBM tumour cell lines (Ge 258, 479 and 518) used were early pas-
sage (7–10) lines derived in our laboratory from brain tumour
resections.
Isolation of HLA class I-bound peptides
Shock-frozen tumour samples were essentially processed as described
previously (Schirle et al., 2000) according to standard protocols
(Falk et al., 1991). Briefly, HLA-A*02 peptide pools from shock-frozen
tissue samples were obtained by immune precipitation from solid tissue
using HLA-specific antibodies, acid treatment and ultrafiltration. To
obtain samples containing HLA-A*02-restricted peptides the antibody
BB7.2 was used (Parham and Brodsky, 1981).
Liquid chromatography–mass
spectrometry
The HLA peptide pools as obtained were separated according to their
hydrophobicity by reversed-phase chromatography (nanoAcquity
UPLC system, Waters) and the eluting peptides were analysed in
an LTQ Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific)
equipped with an electrospray ionization (ESI) source.
Data analysis and peptide
sequence identification
The LC–MS data were collected and automatically processed by ana-
lysing the LC–MS survey (mass signals of unfragmented peptides) as
well as the tandem-MS (MS/MS) data (fragment spectra containing
peptide sequence information). Automated data analysis had been
optimized and adapted for identification of HLA-restricted peptides.
Sequences of peptide vaccine candidates were additionally confirmed
by manual inspection of the fragment spectra. The identity of these
peptides was further assured by comparison of the recorded natural
peptide fragmentation pattern with the fragmentation pattern of a
synthetic sequence-identical reference peptide.
Relative peptide quantification
Label-free relative LC–MS quantitation was performed by ion counting
i.e. by extraction and analysis of LC–MS features (Mueller et al.,
2007). The method assumes that the peptide’s LC–MS signal area
correlates with its abundance in the sample. Extracted features were
further processed by charge state deconvolution and retention time
alignment (Mueller et al., 2007; Sturm et al., 2008). Finally, all LC–
MS features were cross-referenced with the sequence identification
results to combine quantitative data of different samples and tissues
to peptide presentation profiles. The quantitative data were normalized
in a two-tier fashion according to central tendency to account for
variation within technical and biological replicates. Thus each identified
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peptide can be associated with quantitative data allowing relative
quantification between samples and tissues. In addition, all quantita-
tive data acquired for peptide candidates were inspected manually to
assure data consistency and to verify the accuracy of the automated
analysis.
Messenger RNA isolation
Total RNA was prepared from snap frozen GBM samples (n = 20)
using TRIzol (Invitrogen) followed by a cleanup with RNeasy
(QIAGEN); both methods were performed according to the manufac-
turer’s protocol. Total RNA from healthy human tissues (‘bulk’
RNA isolations = mixture of all cell types contained in the respective
tissue) was obtained commercially (Ambion, Clontech, Stratagene and
BioChain). Peripheral blood mononuclear cells were isolated from
blood samples of four healthy volunteers. RNA quality for all RNA
samples was determined using the RNA 6000 Pico LabChip kit on a
2100 Bioanalyzer (Agilent Technologies).
Gene expression analysis
Gene expression analysis of all tumour and normal tissue RNA samples
was performed by Affymetrix Human Genome (HG) U133A or HG-
U133 Plus 2.0 oligonucleotide microarrays (Affymetrix). The same
normal kidney sample was hybridized to both array types to achieve
direct comparability of all samples. All steps were carried out accord-
ing to the Affymetrix manual. An empirical messenger RNA over-
expression score was calculated for each gene considering expression
levels in the analysed GBM samples versus expression in normal
tissues. An empirical cut-off was set in order to prefilter for genes
over-expressed, qualifying the HLA-A*02-derived peptides from
these genes for more detailed analysis as potential targets for GBM
immunotherapy.
Tissue microarray, immunohistochem-
istry and immunofluorescence staining
The tissue microarray consisted of 250 formalin-fixed paraffin-
embedded glioblastoma WHO grade IV and four normal brain tissue
samples as described elsewhere (Campos et al., 2011). Informed
consent was obtained from each patient according to the research
proposals approved by the Institutional Review Board at Heidelberg
Medical Faculty. Antigen retrieval, incubation with primary and
secondary antibodies as well as detection with VECTASTAIN
Laboratories Elite ABC Kit (Vector Laboratories) was carried out as
described (Campos et al., 2011). Each tumour biopsy was evaluated
at  20 magnification by two independent investigators.
In vitro immunogenicity experiments
CD8 + T cells were stimulated three times with artificial antigen-
presenting cells according to Walter et al. (2003) and stained at
Day 21 with HLA/peptide tetramers incorporating either the cognate
peptide or a control peptide. Each peptide was tested in four to six
healthy individuals (9–12 wells per peptide) and in 7 to 11 patients
with GBM (2–5 wells per peptide). For analysis of naı¨ve and memory T
cell populations, fluorescence-activated cell sorted CD8 + CD45RA+
CCR7 + and CD45RA CCR7 + / fractions were similarly stimulated
with artificial antigen-presenting cells.
Flow cytometry and cell sorting
Cultures were stained with HLA/peptide tetramers (5mg/ml) and CD8
antibodies (Beckman Coulter) and analysed using a Gallios flow cyt-
ometer and the Kaluza software (Beckman Coulter) or sorted using a
Vantage SE cytometer (BD Biosciences). Cultures were considered
positive when 41% of tetramer + cells among CD8 + cells were
detected. For intracellular staining experiments, cells were incubated
for 4 h with PMA (phorbol myristate acetate) and ionomycin (both
1 mg/ml, Invitrogen) in the presence of Brefeldin A (1mg/ml,
GolgiPlug, BD Biosciences), fixed with 1% formaldehyde, permeabi-
lized with 0.5% saponin and stained with antibodies to IFN-, IL-2,
CD8 (Beckman Coulter) and IL-4, IL-10, IL-17 (ebioscience).
Generation of T cell clones
Flow cytometry-sorted CD8 + tetramer + cells were plated in limiting
dilution condition (0.3 cells/well) in Terasaki plates (Greiner BioOne) in
Iscove’s Modified Dulbecco’s Medium containing 8% human serum
(Laboratoires Jacques Boy), penicillin, streptomycin, non-essential
amino acids, sodium pyruvate and HEPES (all from Invitrogen) (cyto-
toxic T lymphocyte medium) containing 150 IU/ml IL-2, 1 mg/ml PHA
(phytohaemagglutinin) and allogeneic irradiated (3000 rad) peripheral
blood mononuclear cells (10 000 cells/well). Allogeneic peripheral
blood mononuclear cells were obtained from healthy individuals from
the local blood bank. Cells were further maintained in 96-well plates in
cytotoxic T lymphocyte medium containing 150 IU/ml IL-2 and restimu-
lated periodically (every 3–4 weeks) with 1mg/ml PHA and allogeneic
irradiated peripheral blood mononuclear cells (100 000 cells/well).
Functional T cell assays
For peptide titration experiments, T2 cells were stained with Vybrant
DiD (Invitrogen) and incubated with cytotoxic T lymphocyte clones
and increasing concentration of peptide for 4 h at 37C at an effector
to target ratio of 10:1. Cell death was measured by addition of 7AAD
(Beckman Coulter) and detection of 7AAD+ Vybrant DiD + T2 cells
by flow cytometry. For tumour and K562 cell killing, target cells were
similarly incubated with cytotoxic T lymphocyte clones at an
effector:target ratio of 10:1 unless stated otherwise in presence or
absence of peptide.
Detection of tumour-infiltrating
lymphocytes
Tumour-infiltrating lymphocytes were stained with HLA/peptide tetramers
(5mg/ml) and CD8 after 1 week of culture with PHA (1mg/ml), IL-2
(150 IU/ml) and allogeneic irradiated peripheral blood mononuclear cells.
Results
Identification of the HLA-associated
glioblastoma multiforme peptidome
In order to identify peptides involved in the composition of the
GBM peptidome, we submitted 32 HLA-A*02 + GBM samples to
HLA class I peptide elution and sequenced the isolated peptides by
mass spectrometry. We identified 6820 HLA-restricted peptides,
comprising 3686 different HLA-A*02-restricted sequences eluted
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with the HLA-A*02-specific BB7.2 antibody. At this point, analysis
was discontinued as the rate of newly identified sequences from
the last samples dropped below 15% (i.e. 85% of identified pep-
tides had been identified on other GBM samples before) suggest-
ing that a relevant portion of the accessible HLA-A*02-restricted
GBM peptidome had been discovered. The number of identified
peptides varied between samples (median sequences identified per
sample: 170; range: below 100 to 42000 sequences), which
was due to different amounts of tissue available and possibly
different levels of HLA expression. The peptide composition of
peptidomes also varied among GBM samples, but was more con-
served among GBMs (Pearson correlation R = 0.40) than when
comparing GBM (n = 32) and non-GBM (n = 101) tumours
(Pearson correlation R = 0.08). HLA-A*02 restriction was veri-
fied for all peptides using the SYFPEITHI prediction algorithm
(www.syfpeithi.de). This comprehensive description of the glio-
blastoma peptidome is the first study of its kind on GBM ex
vivo and offers a basis for identification of relevant targets for
immunotherapy.
In order to identify the tumour-associated fraction of the pepti-
dome, we compared expression of the source genes in GBM sam-
ples, normal brain and non-CNS normal tissues using messenger
RNA microarrays. We calculated an empirical messenger RNA
over-expression score for each gene considering expression of
each gene in GBM compared to all normal tissues as well as to
the normal tissue with highest expression. This led to the selection
of 309 peptides (8.4% of the total peptidome). Most of these 309
peptides could unambiguously be assigned to a single human
source gene and were in total derived from 148 different genes,
providing evidence that a broad range of proteins is involved in
the composition of the tumour-associated fraction of the
HLA-associated GBM peptidome.
We performed a protein database and literature search on the
148 proteins identified (Supplementary Table 1) and observed that
39 proteins (26%) were associated with cell proliferation (with 24,
16%, directly involved in cell cycle progression), 27 (18%) with
cell migration and 16 (11%) with cell adhesion, showing that
a large proportion of proteins (450%) is associated with the
malignant phenotype (Fig. 1A). An important fraction of proteins
(22%) was related to nervous system development at the embry-
onic stage, reflecting re-expression in GBM of genes normally
expressed during foetal life. Interestingly, 67 proteins (45%)
have previously been described in the literature to be involved in
non-CNS malignancies, suggesting that an important fraction
of the HLA-associated GBM peptidome is not specific to CNS
tumours but implicated in common tumorigenic mechanisms. In
addition, the large majority (n = 115, 78%) of identified proteins
had not been previously described for GBM to our knowledge,
opening new avenues to explore the biology of this tumour.
Selection and characterization of
glioblastoma multiforme-associated
peptides for immunotherapy
One immediate application provided by a comprehensive know-
ledge of the HLA-restricted GBM peptidome is to focus on the
tumour components that are seen by the immune system and
which could be ideal targets for immunotherapy. We selected
the most attractive candidates based on high messenger RNA
over-expression in GBM (Fig. 1B and C) and potential implication
in gliomagenesis, leading to the identification of 35 peptides.
We further tested these for their ability to elicit strong T cell
responses in vitro using peripheral blood mononuclear cells
from HLA-A*02 + healthy individuals stimulated by artificial anti-
gen-presenting cells loaded with HLA/peptide complexes, and
selected the 10 most immunogenic candidates (Tables 1 and 2)
(Walter et al., 2003). The HLA-A*02 restriction of these peptides
was confirmed using an HLA refolding assay (not shown). As fore-
seen with the design of the selection strategy, the 10 GBM-
associated antigens are involved in tumourigenic mechanisms
(Supplementary Table 2) such as tumour cell motility, proliferation,
invasion or angiogenesis (Sehgal et al., 1998; Kim et al., 2000;
Chekenya et al., 2002; Yang et al., 2004; Phillips et al., 2006;
Mita et al., 2007; Hu et al., 2008). Interestingly, the expression of
most of these antigens is known to correlate with higher tumour
grade or decreased patient survival (Chekenya et al., 1999;
Herold-Mende et al., 2002; Ulbricht et al., 2003; Liang et al.,
2005). In addition, tenascin C can be induced by hypoxia and
TGF-b, which play major roles in GBM progression (Lal et al.,
2001; Hau et al., 2006). Finally, protein tyrosine phosphatase,
receptor-type, Z polypeptide 1 (PTPRZ1) is expressed by embry-
onic stem cells (Soh et al., 2007), and brevican has been described
to be over-expressed in GBM stem cells (Gunther et al., 2008).
To further validate the choice of these peptides, we performed
an in depth expression analysis at the messenger RNA, peptide
and protein levels. Result of the messenger RNA analysis (repre-
sentative example in Fig. 1B) showed a highly enhanced expres-
sion in GBM compared to non-CNS healthy tissues (Fig. 1C) and
normal brain (Fig. 1C). A crucial step was then to confirm that the
selected antigens are also preferentially presented as peptides
at the tumour cell surface. Using a novel mass spectrometry-based
peptide quantification method (Weinschenk et al., 2010; pos-
ter can be downloaded at http://www.immatics.com/index
.php?page=78&modaction=detail&modid=228&modid2=), we
compared natural peptide presentation on GBM, normal brain
and non-CNS normal tissue samples. As depicted in Fig. 1E for a
representative example, we showed that peptides are only weakly
presented at the surface of normal tissues. In contrast, peptides
were presented at high levels at the surface of GBM, with some
heterogeneity among samples. Remarkably, 6 out of 10 peptides
were detected only on tumour cells and the remaining four were
over-presented in the range of 7- to 160-fold on tumour cells as
compared to normal tissues (Fig. 1D). Interestingly among the four
antigens displaying the lowest degree of messenger RNA over-
expression in GBM versus normal brain (Fig. 1C), three were
detected at the peptide level only on tumour cells, emphasizing
the critical value of direct peptide presentation analysis for accur-
ate antigen selection and the poor correlation between messenger
RNA and HLA ligand levels (Weinzierl et al., 2007).
Finally, to get a wide appraisal of antigen expression, we ana-
lysed tissue microarrays containing 221 GBM and 29 recurrent
GBM samples (Campos et al., 2011) by immunohistochemistry
and compared them with normal brain samples. We observed
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intense staining in most GBM samples (representative examples in
Fig. 2A), with absent or faint signals in normal brain. Importantly,
eight out of nine proteins were expressed by 75–100% of
both primary and recurrent GBM samples (Fig. 2A and C;
Herold-Mende et al., 2002), demonstrating an almost ubiquitous
expression in GBM samples. Furthermore, we performed co-
localization studies for the PTPRZ1, CHI3L2 and CSPG4 proteins
and showed that expression was restricted to GFAP + tumour cells
Figure 1 Identification of the HLA-associated GBM peptidome and characterization of selected tumour-associated antigens. (A) Pie chart
displaying the processes in which the tumour-associated source proteins of the HLA-associated GBM peptidome are involved. The total
percentage exceeds 100, as one protein can be involved in several processes. (B) Messenger RNA expression profile of PTPRZ1 plotted
relative to normal brain. Values for normal tissues (green bars) and GBM (red bars) are shown. Each bar represents a single microarray
measurement. (C) Average messenger RNA expression of the peptides in GBM (n = 20) compared to the mean messenger RNA expression
in normal tissues (left y-axis, n = 32) or in normal brain (right y-axis, n = 3). (D) Average peptide presentation on GBM samples relative to
mean of normal tissues. ‘Only on tumours’ indicates that the peptide could not be detected on any normal tissue sample (n = 69) including
additional samples for which peptide quantification was not possible. (E) Peptide presentation profile of the PTPRZ1-derived PTP195–203
peptide. Relative peptide presentation levels for PTP195–203 in all GBM (red bars, n = 12) and all normal tissue samples (green bars, n = 69)
that qualified for relative quantification by objective quality control check. Asterisk indicates not quantifiable. Each bar represents a single
peptide presentation measurement.
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and absent from adjacent endothelial (CD31 +) cells (Fig. 2B). We
detected some PTPRZ1 + microglial (CD68 +) cells (Fig. 2B), how-
ever, only in areas with a high PTPZR1 expression in tumour cells
while it was absent in PTPRZ1-negative tumour areas, as well as in
cases of PTPRZ1-negative tumours (n = 35). Therefore, we inter-
pret this positivity in some microglial cells as phagocytosis of
PTPRZ1 + tumour cells. Finally, and as expected, we noted some
heterogeneity in antigen expression by individual tumour cells
(Fig. 2D), arguing for the use of a panel of tumour-associated
antigens in contrast to single antigens in future vaccines to min-
imize the risk of tumour escape by immunoediting.
Absence of tolerance to the selected
peptides in patients with glioblastoma
multiforme
In order to confirm the choice of the selected peptides for
immunotherapy, we investigated and compared the presence
and function of specific T cells in the blood of HLA-A*02 + pa-
tients with GBM, and HLA-A*02 + healthy individuals. We stimu-
lated peripheral blood mononuclear cell-derived CD8 + T cells with
HLA/peptide complex-loaded artificial antigen presenting cells
(Walter et al., 2003) and detected antigen-specific T cells by tetra-
mer staining. We tested each peptide in peripheral blood mono-
nuclear cells from 7 to 11 patients, with two to five replicates,
depending on peripheral blood mononuclear cell availability.
We detected antigen-specific T cell responses for all peptides in
patients with GBM (representative example in Fig. 3A), with 6
out of 10 peptides inducing a response in 450% of the patients
(Fig. 3B and Table 2). Importantly, peptide immunogenicity, as
defined by combining percentage of responding individuals and
positive wells of the culture plate, was comparable in patients
and healthy donors (Fig. 3C). Overall, these results suggest that
a comparable frequency of antigen-specific T cells is present in
patients with GBM and healthy donors.
In order to further explore the functional status of GBM-specific
T cells, we generated T cell clones with six different antigen spe-
cificities. We then compared those derived from patients
with those from healthy individuals. T cell clones from both (37
analysed in total) shared similar properties regarding cytokine
secretion (Table 3) and avidity of peptide recognition (Fig. 3D
and Table 3). We performed a direct comparison of clones specific
for NLGN4X131–139 or PTP1347–1355 (five clones from patients
with GBM and five from healthy individuals for both specificities,
Table 3) and confirmed the similar avidity of antigen recognition
for patients and healthy donors (mean EC50  SD: NLGN4X131–139:
patients: 34  29 nM, healthy donors: 37  30 nM; PTP1347–1355:
patients: 31  39 nM, healthy donors: 31  23 nM). In addition,
this avidity was comparable to that of antigen–specific T cells
spontaneously primed in vivo by melanoma (Valmori et al.,
2000; Dutoit et al., 2001) or even viruses (Couedel et al., 1999;
Yang et al., 2003; Trautmann et al., 2005). We next assessed
the critical issue of cytotoxicity against GBM cells using patient-
derived T cell clones specific for NLGN4X131–139 and PTP1347–1355.
As shown in Fig. 3E, PTP1347–1355-specific T cells were able to
specifically lyse antigen-expressing HLA-A*02 + tumour cells butT
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not HLA-A*02 antigen + , HLA-A*02 + antigen or HLA-A*02
antigen tumour cells, nor the natural killer-sensitive K562 cell
line. Furthermore, tumour killing was proportional to the effector
to target ratio (not shown). In addition, similar results were
obtained for NLGN4X131–139-specific T cell clones (not shown).
Finally, to assess whether antigen-specific T cells had been
spontaneously elicited by the tumour in patients, we analysed
tumour-infiltrating lymphocytes obtained from GBM resections.
The small size of samples available for research after diagnostic
procedure precluded a direct ex vivo T cell analysis. We therefore
Figure 2 Protein expression analysis. (A) Immunohistochemical analysis of representative proteins on GBM (n = 221), recurrent GBM
(n = 29) and normal brain (n = 4) tissues. Inserts show higher magnification. Scale bars: 50 mm. (B) Immunofluorescent staining of the
PTPRZ1 protein in GBM. Nuclei are shown in blue, PTPRZ1 staining in red and markers specific for endothelial cells (CD31, upper row),
microglial cells (CD68, middle row) and astrocytic tumour cells (GFAP, lower row) in green. Merge is shown on the right. Scale bars:
100 mm. (C and D) Analysis of the percentages of positive tumours (C) or positive individual tumour cells (D).
Table 2 In vitro immunogenicity of the 10 glioma-associated peptides in A*02 + healthy individuals and patients with GBM
Healthy individuals Patients with GBM
Donors Wells Donors Wells
Antigen Total Positive (%) Total Positive (%) Total Positive (%) Total Positive
(%)
BCA478–486 6 6 (100) 66 66 (100) 8 8 (100) 22 21 (95)
CHI10–18 6 6 (100) 60 60 (100) 7 7 (100) 22 18 (82)
CSP21–29 4 4 (100) 42 25 (60) 9 4 (44) 26 6 (23)
FABP7118–126 6 6 (100) 55 33 (60) 7 5 (71) 22 10 (45)
IGF2BP3552–560 6 4 (66) 60 15 (25) 10 2 (20) 29 2 (7)
NLGN4X131–139 5 5 (100) 48 31 (65) 8 5 (63) 23 12 (52)
NRCAM692–700 6 6 (100) 58 10 (17) 9 6 (67) 25 8 (32)
PTP195–203 6 2 (33) 71 9 (13) 11 4 (36) 30 5 (17)
PTP1347–1355 4 4 (100) 37 25 (68) 7 6 (86) 20 13 (65)
TNC3–11 6 6 (100) 65 10 (15) 11 5 (45) 30 9 (30)
Peptide immunogenicity was assessed by repetitive stimulation of CD8 + T cells with polystyrene beads coated with HLA/peptide complex monomers and anti-CD28
antibodies as described in the ‘Materials and methods’ section. T cell responses were detected by staining with phycoerythrin-labelled HLA/peptide tetramer complexes and
a response was considered positive when 41% of tetramer + cells among CD8 + cells were observed. Each peptide was tested in 4 to 6 healthy individuals, with 9–12 wells
per peptide and in 7 to 11 patients with 2–5 wells per peptide.
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amplified tumour-infiltrating lymphocytes (n = 12) using PHA and
interleukin (IL)-2, a procedure that does not bias representation of
antigen-specific T cells (Arenz et al., 1997; Jason and Inge, 1996),
and analysed them after 1 week of culture with tetramers incor-
porating the 10 GBM-associated peptides. Among the tumour-
infiltrating lymphocytes tested, we observed one culture displaying
3% of T cells specific for the BCA478–486 peptide, which corres-
ponds to 12.6% of CD8 + T cells (Fig. 3F). Considering that
brevican protein expression is known to be lost in culture
(Jaworski et al., 1994), we tested antigen recognition and killing
ability with T2 cells. As shown in Fig. 3G, BCA478–486-specific
tumour-infiltrating lymphocytes were able to specifically kill T2
cells loaded with the BCA478–486 peptide but not the control pep-
tide. To our knowledge, these results are the first demonstration
that GBM is able to spontaneously induce an antigen-specific
immune response in the brain microenvironment. To strengthen
Table 3 Functional analysis of antigen-specific T cell clones derived from patients with GBM and healthy individuals
Antigen Donora Clone name Cytokine secretionb Avidity of anti-
gen recognition
IFN- IL-2 IL-17 IL-4 IL-10
BCA478–486 Ge 540 3E4 + + + + +  +  100
Ge 549 1F10 + + + + + +    13
Ge 549 1E8 + + + + +    20
mean  SDd 44  48
HD 057 2A7 + + + + +    25
HD 058 5D1 + + + + + +    80
CHI10–18 Ge 549 1B3 + + + + +    10
HD 057 1C3 + + + + + +    35
HD 057 3D3 + + + + +    50
CSP21–29 Ge 549 10B9 + + + + +    1
Ge 570 1A1 + + + +    20
FABP7118–126 Ge 540 1D1 + + + + + +    38
Ge 549 5F3 + + + + + +    20
Ge 570 1D1 + + + + +    38
mean  SD 32  10
HD 055 3A7 + + + + + +    105
HD 055 1E4 + + + + + +    12
HD 057 2A4 + + + + +    100
HD 058 3A8 + + + + + +    110
mean  SD 82  47
NLGN4X131–139 Ge 540 2E5 + + + + + +    12
Ge 540 3E4 + + + + +    45
Ge 540 1F8 + + + +    25
Ge 549 1E8 + + + + + +    10
Ge 549 2E5 + + + + + +    80
mean  SD 34  29
HD 057 1A7 + + + + +    40
HD 057 5F5 + + + + + +    10
HD 058 5A2 + + + + + +    50
HD 058 3B4 + + + + +    80
HD 058 3B6 + + + + +    5
mean  SD 37  30
PTP1347–1355 Ge 242 4B4 + + + + +    15
Ge 242 2B7 + + + +    10
Ge 522 3B9 + + + + + +    10
Ge 522 5C6 + + + + + +    20
Ge 522 2C5 + + + + +    100
mean  SD 31  39
HD 055 4A6 + + + + +    38
HD 057 4E4 + + + + +    10
HD 057 1E6 + + + + + +    60
HD 057 1B1 + + + + +    40
HD 058 3D2 + + + + + +    5
mean  SD 31  23
a Ge = patients with GBM; HD = healthy individuals.
b Cytokine production by: + , 5–10%; + + , 410–50%; and + + + , 450% of the cells.
c Avidity of antigen recognition as defined by the dose of peptide giving 50% maximal lysis [nM] on T2 cells at an effector to target ratio of 10:1.
d SD = standard deviation; mean and SD are given when at least three clones were tested.
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this observation, the origin of the precursors of BCA478–486-specific
T cells was analysed in peripheral blood. CD45RA + CCR7 + naı¨ve
and CD45RA CCR7 + / memory CD8 + T cell subsets were
sorted by fluorescence-activated cell sorting and stimulated with
artificial antigen-presenting cells incorporating the BCA478–486 pep-
tide or Melan-A26–35 control (Dutoit et al., 2002) peptide. As
shown in Fig. 3H, a response was detected both in the naı¨ve
and memory compartments for BCA478–486-specific T cells, corro-
borating a spontaneous amplification of these cells by the tumour
in vivo.
Discussion
The originality and power of the approach used in this report
to reveal the ex vivo HLA-associated GBM peptidome is a major
advance in tumour immunology. It provides a window on how T
cells can recognize and interact with a brain tumour in vivo. This
was possible thanks to the sensitive technologies now available for
elution and identification of individual peptides in highly complex
mixtures and sophisticated bioinformatics analysis.
A first level of interpretation of the present results is that
they allow a comprehensive view of the spectrum of peptides
and genes expressed by GBM in vivo. While several proteins are
already known to be involved in invasion and many others are
shared by non-CNS tumours, we have now uncovered 115
proteins not previously described to be associated with GBM,
opening new opportunities to explore GBM biology and identify
therapeutic targets. In addition, we show for the first time that a
significant fraction (8.4%) of the peptides presented at the surface
of GBM cells actually derive from tumour-associated proteins.
This number remains an estimate since: (i) tumour biopsies are
not pure populations of tumour cells; (ii) there is a certain
degree of heterogeneity between individual tumour cells; and
(iii) there are variations between patients.
The LC–MS approach undertaken here does not allow us to
ensure that the identified peptides originate from tumour cells
only, as biopsies also contain microglial, endothelial and T cells,
which all express major histocompatibility complex class I. Since
GBM biopsies are usually small in size, using microdissection to
isolate GBM cells would result in a too low cell yield that would
not allow peptidome analysis by LC–MS for the majority of sam-
ples (at least 0.3 g required). Ex vivo sorting of given cell types
(such as GBM or microglial cells) from GBM biopsies would have
the same limitation in the cell number obtained. Using cell lines or
primary cell cultures may be a possibility but resulting peptides are
unlikely to reflect the in vivo situation, which is the strength of our
study. However, despite these technical limitations, we showed
that the cellular origin of these peptides is predominantly the
GBM cells (immunostainings shown in Fig. 2B). Thus, even
taking into account this complexity of tumours in vivo, GBM
cells are likely to present at their surface a large number of
tumour-associated peptides from which peptides used as tumour
rejection antigens can be selected for immunotherapy. Here, we
report 10 peptides derived from proteins involved in tumorigenesis
(Supplementary Table 2) (Sehgal et al., 1998; Kim et al., 2000;
Chekenya et al., 2002; Mita et al., 2007; Hu et al., 2008), which
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are highly expressed in the large majority of the GBM samples
analysed ex vivo, but poorly or not expressed in normal brain
and non-CNS tissues. Interestingly, non-tumoural tissues displayed
some antigen expression at the messenger RNA level but were
devoid of peptide presentation at the cell surface, confirming the
strength of tumour peptidome for antigen selection. We further
validated antigen expression at the protein level in 250 primary or
recurrent GBM samples, a critical step considering the limited
number of initial samples compatible with thorough peptidome
analyses.
Data from this study, together with the knowledge gained in
the last 10 years on the rules of antitumour responses in the brain
(Grauer et al., 2009), provide a scientific background to construct
rational therapies. One obstacle to immunotherapy of GBM is that
research on defining tumour-associated targets for immunother-
apy has until now relied on in vitro or in silico techniques, which
do not necessarily reflect the in vivo situation. Also, research has
also often focused on a limited list of particular oncogenes in
glioma. In contrast, the unbiased generation of knowledge of a
HLA-associated tumour peptidome provides direct access to the
fraction of cellular peptides that are seen by the immune system.
In this regard, it is interesting to note that the set of 3686
peptides identified here did not include previously reported
HLA-A*02-restricted GBM peptides from the EGFRvIII, Eph-2A,
gp100, HER2, IL-13R, MAGE-1, TRP-2, SOX-2, -3, -11 and
WT1-derived peptides (Dunn et al., 2007). Messenger RNA ana-
lysis demonstrated expression of EGFR, HER2, IL-13R, TRP-2,
SOX-2, and -11 by the majority of GBM samples analysed here,
whereas expression of Eph-A2, gp100, MAGE-1, SOX-3 and WT1
was rare or absent. Interestingly, for EGFR and Eph-A2, peptides
other than the previously published ones were identified, confirm-
ing that these proteins are produced and processed in vivo. Thus,
it could be speculated that the previously reported HLA-A*02-
restricted peptides are poorly presented by GBM cells in vivo.
The lack of identification of these peptides could alternatively be
due to the limits of our detection technique; however, the high
sensitivity of the LC–MS used here increases the chance that pep-
tides presented even at very low levels are identified.
We additionally show that the 10 peptides investigated in
this study are highly immunogenic not only in healthy individuals
but also in patients with GBM. Moreover, the presence of the
tumour in the patient group did not change functional properties
of specific T cells tested in vitro. This suggests that no tolerance
was induced by the tumour in patients. This is further supported by
the demonstration of specific tumour killing by patient-derived
GBM-specific T cell clones. In addition, we consistently observed in-
ducible T cell responses in vitro against several antigens in patients
for whom 53 peptides could be tested. If similar multipeptide im-
munogenicity is achieved in vivo in the first clinical trials, multipep-
tide vaccination could be a first step to avoid tumour escape by
immunoediting. This is particularly relevant considering the recent
observation that immunization of patients with GBM with a single
epitope (EGFRvIII) led to antigen loss at the time of tumour progres-
sion (Choi et al., 2009; Sampson et al., 2010). In addition, the future
identification of major histocompatibility complex class II-derived
peptides would be valuable to provide CD4 T cell help. However,
identification of class II ligands by LC–MS is more challenging due to
the structural characteristics of HLA class II molecules and a usually
low HLA class II expression by GBM.
Furthermore, our results seem to indicate that the immune
system of patients with GBM is ignorant of the antigens identified
here, except for the BCA478–486 peptide for which we could detect
antigen-specific tumour-infiltrating lymphocytes in one patient and
precursors in the memory compartment in the periphery for some
individuals. Whilst it is clear that cellular techniques have a thresh-
old of sensitivity, it still appears that the immune system is able to
detect some antigens (even if they are a minority) and not others
at a significant level. One explanation would be that the brevican
antigen is recognized by the immune system through molecular
mimicry, a phenomenon that has been already described for other
antigens such as Melan-A (Dutoit et al., 2002). A wider analysis of
tumour-infiltrating lymphocytes and of the origin of the
antigen-specific precursor in the naı¨ve/memory compartment
(which we are currently undertaking in healthy individuals and
patients with GBM) would help answer these questions.
Whether this ignorance by the immune system can be overridden
by an efficient peptide vaccination is currently being investigated
in the undergoing multi-peptide vaccine trial incorporating 9 out
of the 10 peptides described here.
Finally, the detection of BCA478–486-specific T cells at the
tumour site in one patient (Fig. 3F and G), and in the periphery
among memory T cells in three patients tested (Fig. 3H) suggests
that one of the selected peptides was able to spontaneously elicit
an immune response in vivo, providing support for the tumour
peptidome approach for antigen identification. Apart from being
the first time that spontaneously occurring GBM-specific tumour-
infiltrating lymphocytes are reported, these results also suggest
that GBM-specific T cells have the potential to target the brain
and reach the tumour.
Altogether, this comprehensive inventory of the peptides pre-
sented by GBM cells in vivo is a valuable resource for exploring
the biology of GBM and gives evidence that peptidomes are
important sources of multiple tumour antigens with high potential
for immunotherapy. Regarding the dismal prognosis of patients
with GBM, our results will help to improve the targeting of
vaccination and cell therapy approaches. In a first step towards
the development of efficient immunotherapies, 9 of the 10
peptides (one was omitted due to poor solubility) are now being
developed in a multipeptide therapeutic vaccine designated
IMA950. Recently, two phase I studies in first-line patients with
GBM have started in the UK and USA (clinicaltrials.gov identifier
codes NCT01403285 and NCT01222221). This will allow us to
assess the immunogenicity of the vaccine and set the base to
improve immunization strategies by combining multipeptide
vaccines with the most efficient immunomodulator and other
therapeutic interventions aimed at targeting the immunosuppres-
sive mechanisms taking place in the brain microenvironment.
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